VivoSeq
Oncology

Bile Duct Cancer

30

Pipeline Programs↗

3

Active Trials↗

16

Companies Involved↗

Bile Duct Cancer is an emerging landscape with 30 programs across 16 companies. The most active players are AstraZeneca, PCI Biotech AS, Eastern Cooperative Oncology Group. 4 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

58/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

3 programs

Phase 2P

PCI Biotech AS

2 programs

Phase 2E

Eastern Cooperative Oncology Group

2 programs

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

77%

Small molecule

23 of 30 classified programs — the dominant modality here.

23%ALL OTHERSMonoclonal antibody310%Protein / enzyme13%Cell therapy13%Vaccine13%Radiopharmaceutical13%

Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 97% of 31 pipeline programs.

Analysis

Trial Status

17

clinical trials

Completed7 · 41%
Unknown status2 · 12%
Terminated2 · 12%
Withdrawn2 · 12%
Recruiting2 · 12%
Not yet recruiting1 · 6%
Other1 · 6%

Clinical Trials

Trial Activity

17 trials

Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy
Recruiting·UUniversity of Leipzig·Phase 4·NCT05551299·258 enrolled
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Recruiting·UUniversity of Florida·Preclinical·NCT05000294·29 enrolled
Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer
Not yet recruiting·ZZhang Xiaofeng,MD·Phase 1·NCT06196658·6 enrolled
Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer
Completed·Alliance for Clinical Trials in Oncology·Phase 2·NCT00003276·40 enrolled
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
Completed·EEmory University·Phase 2·NCT03579771·30 enrolled
Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
Completed·TThomas Jefferson University·Phase 2·NCT05328167·16 enrolled
Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers
Completed·—·Phase 2·NCT03003065·10 enrolled
Study of Pembrolizumab and Olaparib in Bile Duct Cancer
Completed·GGeorgetown University·Phase 2·NCT04306367·14 enrolled
Treatment for Bile Duct Cancer in the Liver
Completed·—·Phase 2·NCT02167711·24 enrolled
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Completed·WWake Forest University Health Sciences·Phase 1/2·NCT01766219·17 enrolled
Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer
Suspended·—·Phase 1·NCT00624182·9 enrolled
Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00030511
PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer
Terminated·PPCI Biotech AS·Phase 2·NCT04099888·41 enrolled
Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery
Withdrawn·—·Phase 1·NCT03117855
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
Withdrawn·National Cancer Institute (NCI)·Phase 2·NCT01859182
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)